聚季铵盐-51 | 125275-25-4

• 物质功能分类: 催化剂及助剂 - 聚合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 聚季铵盐-51
• 英文名称: Butyl 2-methylprop-2-enoate;2-(2-methylprop-2-enoyloxy)ethyl 2-(trimethylazaniumyl)ethyl phosphate
• CAS: 125275-25-4
• 化学式: C19H36NO8P
• 分子量: 437.5
• InChiKey: YMBGNWVYKDMNSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.22
• 重原子数：
  29
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  111
• 氢给体数：
  0
• 氢受体数：
  8

制备方法与用途

概述

聚季铵盐-51是一种高效、温和的保湿因子，具有卓越的锁水和保湿性能。它能够有效锁住皮肤和毛发中的水分，即便经过多次水洗后，其保湿效果也不会减弱。涂抹含有聚季铵盐-51的产品后，其成分会在皮肤表面形成一层可呼吸的生物膜，模拟角质层为皮肤提供额外保护，有效减轻表面活性剂对皮肤的刺激，并改善皮肤粗糙、平滑肌肤，同时增强皮肤吸收活性成分的能力。

主要用途

聚季铵盐-51是一种模仿细胞膜设计的活体亲和性原料。它能够抑制各种表面活性剂对活体和细胞的刺激，具有防止皮肤皲裂的效果，还能提高香料的持久性和脂溶性维生素类物质的溶解度。最初应用于生物医药、医疗器械领域的人造血管、人造器官以及生物传感器等方面，在涂覆于人造骨骼或支架表面时，可减少人体排异反应。

功效作用

聚季铵盐-51具有超强保湿性能，其保湿效果是透明质酸的两倍。它能够有效锁住皮肤和毛发中的水分，即便经过多次水洗后，依然保持高效的保湿能力，并能缓解表面活性剂带来的刺激感。

护肤机理

聚季铵盐-51可以在皮肤表面形成一层可呼吸的生物膜，模拟角质层提供额外保护。它有效抑制表面活性剂对皮肤的刺激作用，并改善皮肤粗糙、平滑肌肤，同时增强皮肤吸收活性成分的能力。

文献信息

• LIPID MEMBRANE STRUCTURE
  申请人：Harashima Hideyoshi

  公开号：US20130195962A1

  公开（公告）日：2013-08-01

  A lipid membrane structure for delivering a substance to a target cell having satisfactory cell permeability, selectivity for target cell, and in vivo stability, wherein lipid membrane is modified with (a) a polyalkylene glycol bound with a target cell-selective ligand; and (b) a polypeptide comprising a plurality of arginine residues.

  一种脂质膜结构，用于将物质传递到目标细胞，具有令人满意的细胞渗透性、目标细胞选择性和体内稳定性，其中脂质膜被修饰为：(a)与目标细胞选择性配体结合的聚烷基乙二醇;和(b)包含多个精氨酸残基的多肽。
• LIPID MEMBRANE STRUCTURE WITH NUCLEAR TRANSFERABILITY
  申请人：National University Corporation Hokkaido University

  公开号：EP2572706A1

  公开（公告）日：2013-03-27

  A lipid membrane structure for delivering a substance into a nucleus of a cell, wherein lipid membrane is modified with (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and/or (b) a polypeptide consisting of an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 1, but including deletion and/or substitution and/or insertion of one or several amino acid residues, and having an activity of promoting migration of the lipid membrane structure into a nucleus of a cell, which can efficiently deliver a nucleic acid into a nucleus of an immunocyte such as dendritic cell.

  一种用于向细胞核中递送物质的脂膜结构，其中脂膜由(a)包含 SEQ ID NO: 1 氨基酸序列的多肽修饰，和/或(b)由包含 SEQ ID NO：1 的氨基酸序列组成的多肽，但包括一个或多个氨基酸残基的缺失和/或替代和/或插入，并具有促进脂质膜结构迁移到细胞核中的活性，可有效地将核酸递送到树突状细胞等免疫细胞的细胞核中。
• Controlled-release formulations
  申请人：CAMURUS AB

  公开号：EP2886105A1

  公开（公告）日：2015-06-24

  The present invention relates to formulations of a lipid based controlled-release matrix, a polyhydroxy component and a bioactive agent. Such formulation are useful in the delivery of the bioactive compounds. The invention also relates to the use of a polyhydroxy component for increasing the solubility of a bioactive compound, especially a peptide in a lipid-based controlled-release matrix.

  本发明涉及由脂基控释基质、聚羟基成分和生物活性剂组成的制剂。这种制剂可用于递送生物活性化合物。本发明还涉及使用聚羟基成分来增加生物活性化合物，特别是肽在脂质控释基质中的溶解度。
• Composition for nanoemulsion emulsification, bicontinuous microemulsion, cosmetic, and method for producing same
  申请人：NOF CORPORATION

  公开号：US10357437B2

  公开（公告）日：2019-07-23

  A nanoemulsion emulsification composition including the following components (A) to (D), in which the mass ratios of the components satisfy the following condition, [(A)+(B)]:(C):(D)=1:4 to 8:0.4 to 0.8; component (A) is a copolymer including a constitutional unit (a1) represented by Formula (1) and a constitutional unit (a2) represented by Formula (2), the molar ratio of the constitutional units (a1):(a2) being 5:95 to 60:40, and the weight average molecular weight being 5,000 to 5,000,000; R1 represents a hydrogen atom or a methyl group R2 represents a hydrogen atom or a methyl group, and R3 represents a hydrocarbon group having 12 to 24 carbons; component (B) is a nonionic surfactant having an HLB value of 10 to 14, component (C) is a polyhydric alcohol, and component (D) is water.

  一种纳米乳液乳化组合物，包括以下组分（A）至（D），其中各组分的质量比满足以下条件、 [(A)+(B)]:(C):(D)=1:4 至 8:0.4 至 0.8； 组分(A)是一种共聚物，包括由式(1)表示的构型单元(a1)和由式(2)表示的构型单元(a2)，构型单元(a1):(a2)的摩尔比为 5:95 至 60:40，重量平均分子量为 5,000 至 5,000,000； R1 代表氢原子或甲基 R2 代表氢原子或甲基，R3 代表具有 12 至 24 个碳原子的烃基； 组分（B）是一种 HLB 值为 10 至 14 的非离子表面活性剂，组分（C）是一种多元醇，组分（D）是水。
• Drug eluting stent and method of use of the same for enabling restoration of functional endothelial cell layers
  申请人：SINO MEDICAL SCIENCES TECHNOLOGY INC.

  公开号：US11039942B2

  公开（公告）日：2021-06-22

  The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

  本公开涉及药物洗脱支架，制造、使用和验证药物洗脱支架长期稳定性的方法，以及预测植入药物洗脱支架后支架长期疗效和患者安全性的方法。在一个实施方案中，药物洗脱支架可包括支架框架；含药层；嵌入含药层的药物；以及设置在支架框架上并支撑含药层的生物相容性基底层。含药层的涂层厚度可以不均匀。此外，含药层可配置为在支架植入后 45 天至 60 天之间显著溶解/消散/消失。本公开的支架可降低、减少或消除与植入支架相关的患者风险，例如包括再狭窄、血栓形成和/或MACE。